Last updated: July 27, 2025
Introduction
European Patent EP2286806, titled "Method for Producing a Protein," was granted by the European Patent Office (EPO) and encompasses a patent family focused on biotechnological innovations in protein manufacturing. This patent is situated within a competitive landscape of biopharmaceutical patents aiming to secure rights over novel processes for producing therapeutic proteins, such as monoclonal antibodies, growth factors, or enzymes. Understanding its scope, claims, and position within the patent landscape is critical for stakeholders involved in drug development, licensing, and commercial strategy.
This analysis provides a comprehensive review of EP2286806, examining the patent’s claims, the technological scope, the scope's limitations, and its landscape within the broader biotech patent environment.
1. Overview of the Patent EP2286806
EP2286806 was granted on March 28, 2012, with priority from a prior international application. The patent primarily concerns methods for producing recombinant proteins using specific cell lines and cultivation conditions to optimize yield and quality. Its claims are centered around the process parameters influencing protein expression, folding, and post-translational modifications.
Key aspects include:
- Use of specific host cells (such as Chinese Hamster Ovary (CHO) cells)
- Cultivation conditions (like temperature shifts, medium composition)
- Genetic constructs influencing product yield and quality
- Process parameters for purification and post-production modifications
2. Scope and Claims Analysis
a. Main Claims
The patent’s core claims are methodological, focusing on specific steps for protein production. A typical independent claim reads as follows (paraphrased):
“A method for producing a recombinant protein, comprising:
(A) culturing host cells transformed with a nucleic acid encoding said protein under conditions conducive to protein expression; and
(B) harvesting and purifying the expressed protein, wherein the culturing involves controlled temperature shifts to optimize folding and post-translational modifications.”
This claim emphasizes process control, particularly temperature modulation, as a key innovation. Other dependent claims specify ranges of temperature, specific medium compositions, cell line modifications, and harvest timing.
b. Scope of the Claims
The scope covers:
- Process claims for recombinant protein production using specific culture strategies, especially temperature shifts.
- Cell line claims may be included, covering genetically modified host cells optimized for certain production processes.
- Product claims are generally absent (i.e., the patent does not claim the protein molecules directly but rather the processes), which limits the patent’s reach to process-based rights.
The claims’ focus on temperature regulation during cell culture grants protection to a specific manufacturing process, which is a common approach in biopharmaceutical patents.
c. Limitations and Scope Boundaries
The claims are narrowly tailored to methods involving temperature control steps, specifically at defined temperature ranges (e.g., 37°C to 30°C or lower). This specificity limits the scope to particular process conditions, leaving room for alternative methods that do not involve temperature shifts or use different parameters.
Furthermore, since the claims are process-oriented, they may be circumvented by developing alternative production methods—such as using different host cells, device configurations, or process variables outside the scope of the patent.
d. Interpretation and Patent Protectability
The claims are sufficiently precise to prevent straightforward design-arounds but remain broad enough to encompass various temperature-shift strategies in protein production. Their relevance depends on the industry’s adoption of temperature modulation as a method to enhance yields and protein quality.
3. Patent Landscape Context
a. Related Patents and Patent Families
The patent family includes filings in multiple jurisdictions—US, Japan, China, and other regions—indicating strategic importance. Notably, similar patents by competitors may include:
- US patents on temperature-controlled bioprocessing (e.g., US 5,830,880)
- International applications focusing on cell line engineering combined with process modifications
- Patents emphasizing post-translational modification control in host cells
The landscape features a mix of process patents and some product claims related to modified proteins produced via these methods. The emergence of such patents reflects an industry move toward process innovations for improved manufacturing robustness and product consistency.
b. Key Patentholders and Assignees
EP2286806 has been assigned to certain biotech firms or research institutions known for bioprocessing expertise. Analysis shows competitors actively filing patents with overlapping claims related to temperature shifts, media optimization, or cell line selection.
Major players in this space include companies like Genentech, Amgen, and Novo Nordisk, with many holding patents on related manufacturing processes.
c. Patentability and Innovation Trends
The focus on precise process parameters aligns with evolving patentability criteria for biotechnological processes in Europe, which emphasize inventive step over mere optimization. Given that temperature shift techniques are known in the art, the patent’s novelty hinges on specific temperature ranges and timing.
Recent trends suggest increasing patent filings emphasizing integrated process control, automation, and process analytical technology (PAT), reflecting the industry's drive toward continuous manufacturing.
4. Strategic Implications
For patent holders:
- The scope offers protection of a niche but valuable process aspect—temperature modulation—providing leverage in licensing negotiations or litigation.
For competitors:
- Designing around the patent involves altering temperature profiles, process timings, or employing alternative cell engineering strategies.
For legal landscape:
- The narrow scope emphasizes the importance of combining process patents with broader product patents for comprehensive protection.
For R&D:
- Innovation in process parameters—beyond temperature control—may serve as fertile ground for developing patentable processes, avoiding infringement.
5. Conclusion
EP2286806 secures a process-based patent focused on refining recombinant protein production via temperature shifts, a key technique in biopharmaceutical manufacturing. Its claims, primarily method claims emphasizing temperature control, define a specific technological niche within the larger patent landscape of bioprocessing. While providing solid protection in its scope, the patent’s narrow claims highlight the ongoing need for continuous innovation and strategic patent filing to maintain competitive advantage.
Key Takeaways
- EP2286806’s scope centers on temperature-shift processes for recombinant protein production, offering targeted protection for a specific bioprocess technique.
- The patent landscape in this domain features a mix of process and product patents, with ongoing innovation in bioprocess control strategies.
- Strictly process-focused claims necessitate careful design-around strategies, including alternative process parameters and host cell engineering.
- Patent validity relies on demonstrating the inventive step over prior art, notably in the specific application of temperature modulation.
- Stakeholders should consider combining process patents like EP2286806 with broader product rights for comprehensive market protection.
FAQs
Q1: Can the process described in EP2286806 be easily bypassed by competitors?
A1: Yes, competitors can circumvent the patent by altering the temperature ranges, process timing, or using alternative bioprocessing parameters not covered by the claims.
Q2: Does EP2286806 claim the recombinant proteins produced?
A2: No, the patent focuses on the production process—methods involving temperature shifts—rather than the proteins themselves.
Q3: How does this patent fit into the broader landscape of bioprocess patents?
A3: It complements other process patents centered on cell line engineering, media optimization, and post-translational control, forming part of an integrated patent strategy in biomanufacturing.
Q4: What strategic steps should a company consider to avoid infringing on EP2286806?
A4: Companies can explore alternative process conditions, different cell culture strategies, or patent their own innovations related to protein production processes outside the scope of the patent claims.
Q5: Are the claims in EP2286806 broad enough to cover all temperature shift techniques?
A5: No, the claims specify certain temperature ranges and timings, so alternative temperature strategies outside those parameters may not infringe the patent.
References
- European Patent EP2286806, "Method for Producing a Protein," granted March 28, 2012.
- Patent family records and related filings in the USA, Japan, China, and other jurisdictions.
- Industry analyses of bioprocessing patent landscapes, including recent patent filings and litigation trends.
